Paper42477682
CAR-T and TIL therapies in solid tumors: barriers, clinical lessons, and convergent solutions.
Bach DH and 4 others. Cancer Cell Int, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. CAR-T and TIL therapies in solid tumors: barriers, clinical lessons, and convergent solutions. Papers, record 42477682. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42477682
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- CAR-T and TIL therapies in solid tumors: barriers, clinical lessons, and convergent solutions.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 42806364 | Correction: CAR-T and TIL therapies in solid tumors: barriers, clinical lessons, and convergent solutions. | https://conductscience.org/library/papers/42806364 |
Source PubMed
References133
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29385370 | Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29385370 | PubMed |
| 2 | 29226797 | Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. | N Engl J Med | 2017 | https://conductscience.org/library/papers/29226797 | PubMed |
| 3 | 36821768 | Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. | Blood | 2023 | https://conductscience.org/library/papers/36821768 | PubMed |
| 4 | 38374249 | FDA approves first tumour-infiltrating lymphocyte (TIL) therapy, bolstering hopes for cell therapies in solid cancers. | Nat Rev Drug Discov | 2024 | https://conductscience.org/library/papers/38374249 | PubMed |
| 5 | 33979178 | Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. | J Clin Oncol | 2021 | https://conductscience.org/library/papers/33979178 | PubMed |
| 6 | 36477031 | Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. | N Engl J Med | 2022 | https://conductscience.org/library/papers/36477031 | PubMed |
| 7 | 29686425 | Understanding the tumor immune microenvironment (TIME) for effective therapy. | Nat Med | 2018 | https://conductscience.org/library/papers/29686425 | PubMed |
| 8 | 25838376 | T cell exclusion, immune privilege, and the tumor microenvironment. | Science | 2015 | https://conductscience.org/library/papers/25838376 | PubMed |
| 9 | 29443960 | TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. | Nature | 2018 | https://conductscience.org/library/papers/29443960 | PubMed |
| 10 | 28187284 | Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. | Cell | 2017 | https://conductscience.org/library/papers/28187284 | PubMed |
| 11 | 27433843 | Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27433843 | PubMed |
| 12 | 26205583 | Molecular and cellular insights into T cell exhaustion. | Nat Rev Immunol | 2015 | https://conductscience.org/library/papers/26205583 | PubMed |
| 13 | 26321679 | Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. | Cell | 2015 | https://conductscience.org/library/papers/26321679 | PubMed |
| 14 | 22437938 | Coordinated regulation of myeloid cells by tumours. | Nat Rev Immunol | 2012 | https://conductscience.org/library/papers/22437938 | PubMed |
| 15 | 31359002 | Clonal replacement of tumor-specific T cells following PD-1 blockade. | Nat Med | 2019 | https://conductscience.org/library/papers/31359002 | PubMed |
| 16 | 29033130 | Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. | Cell | 2017 | https://conductscience.org/library/papers/29033130 | PubMed |
| 17 | 30610226 | Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. | Nat Rev Drug Discov | 2019 | https://conductscience.org/library/papers/30610226 | PubMed |
| 18 | 25985798 | TRUCKs: the fourth generation of CARs. | Expert Opin Biol Ther | 2015 | https://conductscience.org/library/papers/25985798 | PubMed |
| 19 | 27427982 | Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. | J Clin Invest | 2016 | https://conductscience.org/library/papers/27427982 | PubMed |
| 20 | 27693353 | Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. | Cell | 2016 | https://conductscience.org/library/papers/27693353 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42806364 | Correction: CAR-T and TIL therapies in solid tumors: barriers, clinical lessons, and convergent solutions. | Cancer Cell Int | 2026 | https://conductscience.org/library/papers/42806364 |
Source PubMed
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CXADRP1 | 653108 | PubTator's text mining | https://conductscience.org/library/genes/653108 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42477682
GET https://conductscience.org/api/papers/v1/42477682/references?page=2